Your browser doesn't support javascript.
loading
Machine learning-based reclassification of germline variants of unknown significance: The RENOVO algorithm.
Favalli, Valentina; Tini, Giulia; Bonetti, Emanuele; Vozza, Gianluca; Guida, Alessandro; Gandini, Sara; Pelicci, Pier Giuseppe; Mazzarella, Luca.
Afiliação
  • Favalli V; Department of Experimental Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy.
  • Tini G; Department of Experimental Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy.
  • Bonetti E; Department of Experimental Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy.
  • Vozza G; Department of Experimental Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy.
  • Guida A; Department of Experimental Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy; Biomedical Translational Imaging Centre, Nova Scotia Health Authority and IWK Health Centre, Halifax, NS B3K 6R8, Canada.
  • Gandini S; Department of Experimental Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy.
  • Pelicci PG; Department of Experimental Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy.
  • Mazzarella L; Department of Experimental Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy. Electronic address: luca.mazzarella@ieo.it.
Am J Hum Genet ; 108(4): 682-695, 2021 04 01.
Article em En | MEDLINE | ID: mdl-33761318
ABSTRACT
The increasing scope of genetic testing allowed by next-generation sequencing (NGS) dramatically increased the number of genetic variants to be interpreted as pathogenic or benign for adequate patient management. Still, the interpretation process often fails to deliver a clear classification, resulting in either variants of unknown significance (VUSs) or variants with conflicting interpretation of pathogenicity (CIP); these represent a major clinical problem because they do not provide useful information for decision-making, causing a large fraction of genetically determined disease to remain undertreated. We developed a machine learning (random forest)-based tool, RENOVO, that classifies variants as pathogenic or benign on the basis of publicly available information and provides a pathogenicity likelihood score (PLS). Using the same feature classes recommended by guidelines, we trained RENOVO on established pathogenic/benign variants in ClinVar (training set accuracy = 99%) and tested its performance on variants whose interpretation has changed over time (test set accuracy = 95%). We further validated the algorithm on additional datasets including unreported variants validated either through expert consensus (ENIGMA) or laboratory-based functional techniques (on BRCA1/2 and SCN5A). On all datasets, RENOVO outperformed existing automated interpretation tools. On the basis of the above validation metrics, we assigned a defined PLS to all existing ClinVar VUSs, proposing a reclassification for 67% with >90% estimated precision. RENOVO provides a validated tool to reduce the fraction of uninterpreted or misinterpreted variants, tackling an area of unmet need in modern clinical genetics.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Mutação em Linhagem Germinativa / Aprendizado de Máquina Tipo de estudo: Guideline / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Mutação em Linhagem Germinativa / Aprendizado de Máquina Tipo de estudo: Guideline / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article